Recruiting

Histotripsy

Sponsor:

UCLA

Code:

NCT07470008

Conditions

Soft Tissue Neoplasm

Soft Tissue Cancer

Soft Tissue Lesion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Medical Record Review

Study Details

Brief summary:

Histotripsy is a treatment that uses focused ultrasound waves to break down tissue without surgery. The ultrasound waves meet at a specific spot and turn the tissue into liquid. This study is a prospective observational registry of participants receiving histotripsy. The goal of this study is to gather information about the use of histotripsy to confirm it is safe and effective medical procedure.

Conditions

Soft Tissue Neoplasm

Soft Tissue Cancer

Soft Tissue Lesion

Study ID

NCT07470008

Start date

Jan 29, 2026

Status verified date

Mar, 2026

Completion date

Aug 8, 2031

Anticipated

Primary completion date

Aug 8, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All adult patients who are treated with histotripsy per standard clinical care at University of California San Francisco (UCSF) are eligible for inclusion in the registry.

Exclusion Criteria:

  • Children/minors, and adults who lack decision-making capacity, will be excluded from the registry. Patients who do not consent for inclusion in the registry will also be excluded.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with Soft Tissue Tumors

Participant data will be collected from participants' medical records. Cancer history, laboratory analysis, histotripsy procedure details, adverse events, and oncological outcomes of the procedure along with demographic data will be collected.

Interventions

Medical Record Review

Data will be collected from the participants medical records.

Primary outcome measure

  • Frequency of overall tumor response across all participants [ Time Frame: up to 3 years ]
  • Proportion of participants experienced an adverse event [ Time Frame: Up to 3 years ]
  • Progression free survival (PFS) [ Time Frame: up to 3 years ]
  • Overall Survival (OS) [ Time Frame: Up to 3 years ]

Central Contacts and Locations

Central contacts

Ryan Lokken, MD

877-827-3222cancertrials@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Ryan Lokken, MD

877-827-3222cancertrials@ucsf.edu

Principal Investigator:

Ryan Lokken, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Mar 17, 2026

Last verified

Mar, 2026

Keywords

  • Histotripsy
  • Ablation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-03-17.